The application from Lykos — a drug enterprise incubated via the Multidisciplinary Affiliation for Psychedelic Research, or MAPS — arrived on the FDA under a cloud of controversy. Former demo members had alleged adverse events weren't described — which include feelings of suicidality following the treatment — Which bias between All those ru